{"title":"Psychobiology of premenstrual dysphoric disorder.","authors":"B L Parry","doi":"10.1055/s-2008-1067968","DOIUrl":null,"url":null,"abstract":"<p><p>Premenstrual Dysphoric Disorder (PMDD) is the new terminology used in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). It more rigorously defines criteria for what historically has been referred to as premenstrual syndrome (PMS). Based on studies of its phenomenology and course, PMDD was categorized in DSM-IV as a depressive mood disorder. Findings support low serotonin and melatonin metabolism in PMDD compared with healthy control subjects, and an increasing number of rigorous studies report a reduction of symptoms with selective serotonin reuptake inhibitors (SSRIs).</p>","PeriodicalId":79457,"journal":{"name":"Seminars in reproductive endocrinology","volume":"15 1","pages":"55-68"},"PeriodicalIF":0.0000,"publicationDate":"1997-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2008-1067968","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in reproductive endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-2008-1067968","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27
Abstract
Premenstrual Dysphoric Disorder (PMDD) is the new terminology used in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). It more rigorously defines criteria for what historically has been referred to as premenstrual syndrome (PMS). Based on studies of its phenomenology and course, PMDD was categorized in DSM-IV as a depressive mood disorder. Findings support low serotonin and melatonin metabolism in PMDD compared with healthy control subjects, and an increasing number of rigorous studies report a reduction of symptoms with selective serotonin reuptake inhibitors (SSRIs).